| 体内研究: |
DM1-SMe (15 mg/kg in form of IMGN901, iv, three times a week for 6 weeks) 在异种移植小鼠模型中具有抗肿瘤活性。 |
| 参考文献: |
1. Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. 2. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.275 ml |
6.374 ml |
12.749 ml |
| 5 mM |
0.255 ml |
1.275 ml |
2.55 ml |
| 10 mM |
0.127 ml |
0.637 ml |
1.275 ml |
| 50 mM |
0.025 ml |
0.127 ml |
0.255 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |